Comparison of IL‐2‐antibody to IL‐2‐Fc with or without stereotactic radiation therapy in CEA immunocompetent mice with CEA positive tumors

• Published in: Cancer medicine (Malden, MA) Vol. 13; no. 3; pp. e6909 - n/a
• Main Authors: Williams, Lindsay, Li, Lin, Yazaki, Paul J., Wong, Patty, Hong, Teresa, Poku, Erasmus K., Hui, Susanta, Ghimire, Hemendra, Shively, John E., Kujawski, Maciej
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.02.2024; Wiley
• Subjects: Antibodies; Antitumor activity; Biodistribution; Breast cancer; Cancer therapies; CD4 antigen; CD8 antigen; colon cancer; Colorectal cancer; Cytokines; Fc receptors; Flow cytometry; Foxp3 protein; Fusion protein; Immune clearance; Immunocompetence; immunocytokines; Immunological memory; immunotherapy; Interleukin 2; Lymphocytes T; Proteins; Radiation therapy; Software; Toxicity; Transgenic mice; Tumors; γ-Interferon; breast cancer; immunocytokines; colon cancer; immunotherapy; radiation therapy

Background The potent immune effects of interleukin‐2 (IL‐2) for cancer therapy can be increased by genetic fusion of IL‐2 to the Fc domain of an antibody (IL‐2‐Fc) or tumor targeted by genetic fusion to a whole antibody known as an immunocytokine (ICK). Methods An anti‐CEA ICK (M5A‐IL‐2) was compar...